TI - Structure of the <p1  pair=1 >  <prot>  MDM2 </prot>  </p1>  oncoprotein bound to the <p2  pair=1 >  <prot>  p53 </prot>  </p2>  tumor suppressor transactivation domain .
PG - 948 - 53 AB - The <p1  pair=2 >  <p1  pair=3 >  <prot>  MDM2 </prot>  </p1>  </p1>  oncoprotein is a cellular inhibitor of the <p2  pair=2 >  <prot>  p53 </prot>  </p2>  tumor suppressor in that it can bind the transactivation domain of <p2  pair=3 >  <prot>  p53 </prot>  </p2>  and downregulate its ability to activate transcription .
In certain cancers , <prot>  MDM2 </prot>  amplification is a common event and contributes to the inactivation of <prot>  p53 </prot>  .
The crystal structure of the 109 - residue amino - terminal domain of <p1  pair=4 >  <prot>  MDM2 </prot>  </p1>  bound to a 15 - residue transactivation domain peptide of <p2  pair=4 >  <prot>  p53 </prot>  </p2>  revealed that <p1  pair=5 >  <prot>  MDM2 </prot>  </p1>  has a deep hydrophobic cleft on which the <p2  pair=5 >  <prot>  p53 </prot>  </p2>  peptide binds as an amphipathic alpha helix .
The interface relies on the steric complementarity between the <prot>  MDM2 </prot>  cleft and the hydrophobic face of the <prot>  p53 </prot>  alpha helix and , in particular , on a triad of <p1  pair=6 >  <prot>  p53 </prot>  </p1>  amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the <p2  pair=6 >  <prot>  MDM2 </prot>  </p2>  cleft .
These same <prot>  p53 </prot>  residues are also involved in transactivation , supporting the hypothesis that <p1  pair=7 >  <prot>  MDM2 </prot>  </p1>  inactivates <p2  pair=7 >  <prot>  p53 </prot>  </p2>  by concealing its transactivation domain .
The structure also suggests that the amphipathic alpha helix may be a common structural motif in the binding of a diverse family of transactivation factors to the <prot>  TATA - binding protein </prot>  - associated factors .
AD - Cellular Biochemistry and Biophysics Program , Memorial Sloan - Kettering
